.svg)
Advancing treatments for patients
with a history of kidney stones
.png)
Lilac Therapeutics is a clinical-stage company dedicated to developing treatments to prevent recurrent kidney stones.
Approximately 1 in 11 people in the United States have had a kidney stone. Kidney stones result in over 1.5 million visits to emergency departments annually, with 1 in 5 patients hospitalized.
Kidney stones can result in excruciating pain, bloody urine, blockage of urine flow, urinary tract infections, and sepsis. Patients with kidney stones are also at increased risk of kidney failure. Patients who have had one kidney stone are at increased risk for having future kidney stones, and for most patients there are no approved treatments to prevent future kidney stones and related complications.
.svg)
The most common type of kidney stone is composed of calcium oxalate, which form when calcium and oxalate in the urine precipitate to form crystals. Urinary oxalate levels directly correlate with risk of stone formation.
Lilac Therapeutics is developing LLX-424 as a treatment to prevent recurrent calcium oxalate kidney stones. LLX-424 is a small molecule glycolate oxidase inhibitor designed to block liver synthesis of oxalate, reduce the levels of oxalate in the urine, and decrease the risk and clinic impact of kidney stones.
.svg)
%20(1).png)
.png)
.png)
%20(1).png)
%20(1).png)
%20(1).png)
.png)
%20(1).png)
%20(1).png)
.svg)
Jan. 2025
.png)
Oct. 2022
Dec. 2020
.png)
.svg)
.png){kind=small}